Global Distribution Expansion The company has established distribution partnerships with regional players to expand access to SYNTAX across Latin America, Japan, and South Korea. Focus on channel sales, regional localization, and service capabilities to accelerate adoption of in house, on demand DNA synthesis.

Strategic Collaborations A network of collaborations with EVA Pharma, Quantoom, and Gencell, along with BMS and BioStream, positions DNA Script in vaccine, mRNA, and oligo supply chains. Target pharma and biotech manufacturers seeking to bring production in house, offering turnkey SYNTAX integration and support.

Competitive Differentiation SYNTAX enables benchtop enzymatic DNA synthesis for rapid, in house DNA production, offering speed and cost advantages over traditional chemical synthesis. Position to genomics labs and biotech startups needing fast prototyping and reduced outsourcing timelines.

Channel Readiness Given reliance on distributors and partners, develop reseller, OEM, and integrator programs with regional parties to scale reach, provide training, and align with GMP and quality requirements.

Leadership Momentum A new CEO has been appointed and a cadence of partnerships and expansions is underway, signaling renewed growth and a focus on commercializing the SYNTAX platform to larger enterprise and research customers.